This segment focuses on the development, manufacturing, and marketing of Human Leukocyte Antigen (HLA) typing and genotyping products and services. TBG Diagnostics offers a range of kits, including ExProbe HLA and HPA kits, Morgan SSP HLA kits, and HLAssure SBT HLA Kits, utilizing real-time PCR techniques and sequence-specific primers and probes. The company also provides AccuType SBT analysis software and Morgan SSPal HLA Typing Analysis Software for result interpretation. Research and development activities include continuous improvement of existing products and the development of new HLA typing solutions. The company's technologies are crucial for transplantation donor selection and matching, improving patient outcomes in transplantation. Market positioning is strong due to the company's focus on high-resolution HLA genotyping and its partnerships with clinical labs, blood centers, and bone marrow registry labs. Future opportunities include expansion into new markets and the development of next-generation sequencing (NGS) based HLA typing solutions. Regulatory compliance and clinical validation are critical aspects of this segment, ensuring the accuracy and reliability of HLA typing results. Partnerships with medical institutions and diagnostic companies are essential for market access and distribution.

This segment encompasses the development, manufacturing, and distribution of COVID-19 testing kits. TBG Diagnostics offers testing solutions to clinical labs and other healthcare providers. The company's research and development efforts focus on improving the accuracy, sensitivity, and speed of COVID-19 tests. Technologies used include real-time PCR. The primary therapeutic area is infectious diseases, specifically the detection of SARS-CoV-2. The patient impact is significant, as timely and accurate testing is crucial for controlling the spread of the virus and enabling effective treatment. Market positioning is influenced by competition from other diagnostic companies and the evolving regulatory landscape. Future opportunities include the development of new diagnostic tests for emerging variants and other infectious diseases. Regulatory approvals and clinical validation are essential for market access. Partnerships with healthcare providers and distributors are important for reaching target markets.